Serum prognostic markers in head and neck cancer

Source: Clincancerres François Meyer1, Élodie Samson1,2, Pierre Douville1, Thierry Duchesne2, Geoffrey Liu3 and Isabelle Bairati1 Authors' Affiliations:1Laval University Cancer Research Center and 2Département de Mathématiques et Statistique, Laval University, Quebec, Quebec and 3Medical Biophysics Department, Ontario Cancer Institute/Princess Margaret Hospital, Toronto, Ontario, Canada Corresponding Author:François Meyer, Cancer Research Center, Laval University, CHUQ, HDQ, 11, Cote Du Palais, Quebec, Quebec, G1R 2J6 Canada. Phone: 418-525-4444-15581; Fax: 1-418-691-2970; E-mail: [email protected]. Abstract Purpose: Recognized prognostic factors do not adequately predict outcomes of head and neck cancer (HNC) patients after their initial treatment. We identified from the literature nine potential serum prognostic markers and assessed whether they improve outcome prediction. Experimental Design: A pretreatment serum sample was obtained from 527 of the 540 HNC patients who participated in a randomized controlled trial. During follow-up, 115 had a HNC recurrence, 110 had a second primary cancer (SPC), and 216 died. We measured nine potential serum prognostic markers: prolactin, soluble interleukin-2 (IL-2) receptor-α, vascular endothelial growth factor, IL-6, squamous cell carcinoma antigen, free β-human choriogonadotropin, insulin-like growth factor-I, insulin-like growth factor binding protein-3, and soluble epidermal growth factor receptor. Cox regression was used to identify a reference predictive model for (a) HNC recurrence, (b) SPC incidence, and (c) overall mortality. Each serum marker was added in turn to these reference models to determine by the likelihood ratio test whether it significantly improved outcome prediction. We controlled for the false discovery rate that results from multiple testing. Results: IL-6 was the only serum marker that significantly improved outcome prediction. Higher [...]

2010-01-29T19:47:27-07:00January, 2010|Oral Cancer News|

Incense linked to cancer

Source: www.cavalierdaily.com Author: Surabhi Bhatt Burning incense is an age-old practice in many cultures’ religious and spiritual ceremonies — especially in Asia — and its use has gained popularity in Western countries as well.  Researchers at the Statens Serum Institute in Copenhagen, Denmark, however, have raised concerns about the possible health risks associated with long-term exposure to incense. Led by Dr. Jeppe T. Friborg of the Epidemiology Department, the study followed more than 61,000 cancer-free Singaporean Chinese men and women between the ages of 45 and 74 from 1993 to 2005.  Participants were asked to report on their average incense use in their homes, including how often they burned it and for how long.  During the study’s 12-year duration, 325 men and women developed cancer of the upper respiratory tract, such as nasal, oral or throat cancer.  Another 821 developed lung cancer. Although the overall risk of lung cancer was not found to increase with incense use, the study suggested that greater incense use can lead to a heightened risk of developing squamous cell carcinoma of the lung, which is the second most common type of lung cancer. Some supporting evidence may be that the burning materials from which incense is derived — including oils and plant materials — have been found to produce potentially cancer-causing substances, including benzene and polyaromatic hydrocarbons. Friborg’s study, though, is the first to link long-term incense use to an increased risk of developing cancer.

BioVex Agrees SPA With the FDA for a Pivotal Phase III Study With OncoVEX (GM-CSF) in Head and Neck Cancer

Source: PR Newswire Author: Staff WOBURN, Mass., Sept. 15 /PRNewswire/ -- BioVex Inc, a biotechnology company developing clinical stage treatments for cancer and the prevention of infectious disease, announced today that the U.S. Food and Drug Administration (FDA) has approved the design of a single, pivotal, Phase III clinical trial evaluating its lead product, OncoVEX (GM-CSF), for the first-line treatment of patients with squamous cell cancer of the head and neck. The study is the second the Company has agreed with the FDA under the Special Protocol Assessment (SPA) procedure and highlights the broad potential utility of BioVex's first-in-class cancer destroying virus technology. The first SPA was in melanoma under which BioVex is currently conducting a pivotal Phase III trial. Patients with head and neck cancer often present with locally advanced, bulky disease that is too large, or too close, to vital organs to remove surgically. These patients typically undergo combination radiation and chemotherapy treatment, in some cases with additional surgery. Patients who present with tumor-containing lymph nodes are particularly difficult to treat and approximately half of these patients relapse within two years. Philip Astley-Sparke, President & CEO, for BioVex said: "The announcement of our second SPA governing a Phase III study demonstrates the breadth of the commercial opportunity with OncoVEX (GM-CSF). In addition to treating metastatic disease as is the intention in our ongoing Phase 3 study in melanoma, following multiple systemic responses in Phase II, OncoVEX (GM-CSF) also has considerable potential utility in treating discrete solid tumor masses [...]

2009-09-16T16:29:05-07:00September, 2009|Oral Cancer News|

New radiotherapy technique proven safe, less toxic for cancer patients, University Of Pittsburgh Cancer Institute study finds

Source: Medicalnewstoday.com Author: Staff A new technique known as stereotactic body radiotherapy (SBRT) is safe for patients with recurrent head and neck cancers and may improve their quality of life, according to researchers from the University of Pittsburgh Cancer Institute (UPCI). Results of the phase I study were reported today in the International Journal of Radiation Oncology, Biology, Physics. Each year approximately 500,000 cases of squamous cell carcinoma of the head and neck are diagnosed worldwide. While treatment has improved with advances in surgery, radiation and chemotherapy, more than half of patients will die from recurrent disease. Treatment options for patients with recurrent disease are limited, and for many, surgery may not be an option, according to principal investigator Dwight E. Heron, M.D., director, Radiation Oncology Services, UPMC Cancer Centers. "Chemotherapy alone can provide this patient population some palliation and pain relief, but it doesn't prolong survival," said Dr. Heron. "A few patients may be able to receive additional radiation treatments, but head and neck cancers, by their very nature, develop in very delicate areas of the body, which provide significant retreatment challenges." SBRT may offer these patients an alternative, noted Dr. Heron. "At the completion of our study, we found this treatment was tolerated very well. No maximum tolerated dose was reached, and no toxicities occurred that caused us to limit the dosing." SBRT is a relatively new technique using CyberKnife® technology, which delivers high doses of radiation with more precision than conventional techniques. The vast majority of patients complete [...]

2009-06-21T06:01:15-07:00June, 2009|Oral Cancer News|

Preoperative smoking cessation improves head and neck surgery outcomes

Source: Cancerpage.com Author: Staff NEW YORK (Reuters Health) - Even a short period of 4 to 8 weeks of smoking cessation prior to surgery to treat upper aerodigestive tract squamous cell carcinoma improves wound healing, according to a review of the literature. If the patient stays tobacco-free, the risk of cancer recurrence is substantially reduced. However, full cessation is required -- simply reducing the quantity of cigarettes smoked per day is of little benefit, Dr. Richard O. Wein from Tufts Medical Center, Boston, reports in the June Archives of Otolaryngology-Head and Neck Surgery. Studies of the impact of smoking cessation on surgical outcomes within the field of otolaryngology are few and contradictory, Dr. Wein points out. For his review, he drew on studies of smokers operated on for non-otolaryngology conditions as well as for head and neck tumors. The "bottom line," he says, is that "although conflicting reports exist within the literature concerning the impact of short-term smoking cessation, it should be noted that the sheer number of articles reporting the negative impact of continued tobacco use on postoperative pulmonary function and wound healing far outweighs those minimizing this impact." Furthermore, multiple studies indicate increased risk of recurrence or the development of a second cancer in patients who continue to smoke after their index cancers are diagnosed. One study, for example, found that 40% of patients who kept smoking after being treated definitively for a malignant oral cavity tumor had a recurrence or developed a second malignant lesion. Overall costs of care, the author [...]

2009-06-19T07:38:56-07:00June, 2009|Oral Cancer News|

Oral Cancer Survivor To Expose Dangers Of Chew Tobacco

Source: Middlesex-London Health Unit Author: Staff For Gruen Von Behrens, an encounter with chewing tobacco on a camping trip nearly two decades ago led to an addiction that not only changed his life, but the lives of hundreds of thousands of teens across North America who have heard his story. Today, the 31 year-old from Illinois tours the continent, using his life story as the backdrop for what can happen when teens get hooked on "Chew". Once a talented young baseball player with dreams of cracking a big league lineup, Von Behrens, has undergone more than 40 surgeries to rebuild his face and jaw, all necessary after he developed squamous cell carcinoma at 17, all consequences of his addiction to chewing tobacco. x-London Health Unit, its Youth Action Alliance, the One Life Crew, the Thames Valley District School Board and the London and District Catholic School Board are pleased to be hosting Von Behrens as he brings his "How Chew Tobacco Gave Me Cancer" presentation to London and Middlesex County next week. Von Gruen’s schedule will see him in London on Monday and Tuesday, then Strathroy on Wednesday and Thursday; a complete schedule of presentations follows this news release. While most of the presentations Gruen Von Behrens will make are specifically aimed at the student body at local high schools, the community will be able to hear his message on Thursday, June 11th at 7:00 p.m. at A. B. Lucas Secondary School in London. Sports teams are encouraged to attend this [...]

2009-06-08T09:56:52-07:00June, 2009|Oral Cancer News|

Chest scans may help monitor spread of head and neck cancer in high-risk patients

Source: www.sciencedaily.com Author: staff Among high-risk patients with head and neck cancer, chest computed tomography (CT) may help detect disease progression involving the lungs, according to a new report. Developing a second, distant cancer (a metastasis or a new primary cancer) is an important factor affecting survival of patients with head and neck squamous cell carcinoma, which accounts for most head and neck cancers, according to background information in the article. The most common site at which such patients develop new metastases is the lungs, with an incidence of 8 percent to 15 percent. Chest X-rays are the most commonly used screening tool for detecting these malignancies but do not always identify early abnormalities. Yen-Bin Hsu, M.D., of Taipei Veterans General Hospital, Taiwan, and colleagues evaluated 270 screening chest CT scans performed over 42 months in 192 patients with head and neck squamous cell carcinoma. The scans were categorized as new cases, follow-up cases or recurrent cases, and results classified as normal or abnormal. Of the 270 scans, 79 (29.3 percent) were considered abnormal, including 54 (20 percent) that identified a malignant neoplasm of the lung and 25 (9.3 percent) showing indeterminate abnormalities. "The rate of an abnormal scan was significantly higher in the follow-up case group (44.2 percent) than in the new case group (14.2 percent)," the authors write. Patients whose cancer was classified as stage N2 or N3 (indicating some degree of lymph node involvement), who had stage IV disease (in which the cancer has spread to another [...]

Burning incense increases risk of respiratory tract cancers

Source: ScienceDaily (www.sciencedaily.com) Author: staff Long term use of incense increases the risk of developing cancers of the respiratory tract, according to a new study. The new analysis, which the authors say is the first prospective investigation of incense and cancer risk, appears in the October 1, 2008 issue of CANCER, a peer-reviewed journal of the American Cancer Society. Incense is an integral part of daily life in large parts of Asia. Researchers have shown that burning incense—which is made of plant materials mixed with oils—produces a mixture of possible carcinogens, including polyaromatic hydrocarbons, carbonyls and benzene. Because incense smoke is inhaled, a number of studies have looked at the possible link between incense burning and lung cancer, but results have been inconsistent. In addition, the possible association of incense use and other respiratory tract cancers has not been analyzed. To investigate this, Dr. Jeppe Friborg of the Statens Serum Institut in Copenhagen, Denmark and colleagues in Singapore and the U.S. studied the associations between exposure to incense and the whole spectrum of respiratory tract cancers in a large population in Singapore. The study involved 61,320 Singapore Chinese who were free of cancer and aged 45-74 years in 1993-1998. At that time, they completed a comprehensive interview on living conditions and dietary and lifestyle factors. The investigators followed these individuals through 2005, noting which participants developed cancer during that time. Dr. Friborg's team documented a total of 325 upper respiratory tract cancers (including nasal/sinus, tongue, mouth, laryngeal and other cancers) [...]

Go to Top